Payment For Outcomes Key To EU Market Access for Yescarta
Payment for outcomes has played an important role in enabling Gilead to secure reimbursement for Yescarta in some EU markets. It is likely to be the key focus for the company as it works to expand patient access to the potentially transformative CAR-T therapy across Europe.
You may also be interested in...
The Scottish health technology appraisal body, the SMC, has okayed Gilead’s CAR-T therapy Yescarta for use on the Scottish National Health Service.
Scotland’s health technology assessment body has reversed its earlier decision to reject Kymriah for DLBCL.
Novartis has managed to temporarily overcome payer reservations about the real-world value of Kymriah by engaging early with payers and heath technology assessment bodies and by developing tailored outcomes-based deals for key European markets. Approaching each payer with a responsible attitude has helped too.